Subclinical GvHD in non-irradiated F1 hybrids: Severe lymphoid-tissue GvHD causing prolonged immune dysfunction

Bone Marrow Transplantation

Volumn 46, Issue 4, 2011, Pages 586-596

  Sprangers, B ^a   Van Wijmeersch, B ^a   Luyckx, A ^a   Sagaert, X ^a   Verbinnen, B ^a   Rutgeerts, O ^a   Lenaerts, C ^a   Tousseyn, T ^a   Dubois, B ^a   Waer, M ^a   Billiau, A D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

APC; GvHD; mouse; parental splenocyte infusion

Indexed keywords

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW DEPRESSION; CHIMERA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; IMMUNOCOMPETENCE; IMMUNOPATHOLOGY; LYMPHOCYTOPENIA; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL TRANSPLANTATION; CHIMERA; GRAFT REJECTION; GRAFT VS HOST DISEASE; IMMUNE SYSTEM; LYMPHOID TISSUE; MICE; MICE, INBRED C57BL; SPLEEN;

EID: 79953692708     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.162     Document Type: Article

References (37)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
2. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005; 11: 1244-1249. (Pubitemid 43093673)
3. Chakraverty R, Cote D, Buchli J, Cotter P, Hsu R, Zhao G et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006; 203: 2021-2031. (Pubitemid 44188475)
4. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplant-ation in older patients with hematologic malignancies: repla-cing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
5. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
6. De Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73-78. (Pubitemid 32124409)
7. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmye-loablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
8. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909. (Pubitemid 34925172)
9. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leu-kemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002; 100: 1894-1902. (Pubitemid 34925171)
10. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320-329. (Pubitemid 38351817)
11. Koh LP, Chao N. Haploidentical hematopoietic cell trans-plantation. Bone Marrow Transplant 2008; 42(Suppl 1): S60-S63.
12. Rus V, Svetic A, Nguyen P, Gause WC, Via CS. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995; 155: 2396-2406.
13. Murphy WJ. Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes. J Clin Invest 2000; 106: 745-747.
14. Tschetter JR, Mozes E, Shearer GM. Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J Immunol 2000; 165: 5987-5994.
15. Bloom ML, Wolk AG, Simon-Stoos KL, Bard JS, Chen J, Young NS. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol 2004; 32: 1163-1172. (Pubitemid 39601122)
16. Chen J, Lipovsky K, Ellison FM, Calado RT, Young NS. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood 2004; 104: 1671-1678. (Pubitemid 39202273)
17. Chen J, Brandt JS, Ellison FM, Calado RT, Young NS. Defective stromal cell function in a mouse model of infusion-induced bone marrow failure. Exp Hematol 2005; 33: 901-908. (Pubitemid 40982656)
18. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol 1987; 139: 1840-1849. (Pubitemid 17141612)
19. Billiau AD, Sefrioui H, Overbergh L, Rutgeerts O, Goebels J, Mathieu C et al. Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras. Transplantation 2001; 71: 292-299. (Pubitemid 32126115)
20. Fevery S, Billiau AD, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 2007; 21: 1451-1459. (Pubitemid 46965286)
21. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Transient expansion of Mac1+Ly6-G+Ly6-C+ early mye-loid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 2003; 102: 740-748. (Pubitemid 36842001)
22. Van Wijmeersch B, Sprangers B, Rutgeerts O, Lenaerts C, Landuyt W, Waer M et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol Blood Marrow Transplant 2007; 13: 627-637. (Pubitemid 46768004)
23. Rolink AG, Pals ST, Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. J Exp Med 1983; 157: 755-771. (Pubitemid 13145074)
24. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inacti-vation of host antigen-presenting cells. Science 1999; 285: 412-415. (Pubitemid 29343964)
25. Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510-517. (Pubitemid 38667910)
26. Vossen JM, Heidt PJ, van den BH, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23. (Pubitemid 20046730)
27. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-prospective randomized trial. Blood 1999; 93: 3267-3275. (Pubitemid 29220893)
28. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003; 4: 154-160. (Pubitemid 36193017)
29. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654. (Pubitemid 41113195)
30. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267: 216-225.
31. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 4583-4592. (Pubitemid 41361997)
32. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008; 181: 3291-3300.
33. Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 2007; 178: 2893-2900. (Pubitemid 46333167)
34. Wang H, Asavaroengchai W, Yeap BY, Wang MG, Wang S, Sykes M et al. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood 2009; 113: 3612-3619.
35. Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 1996; 157: 4811-4821. (Pubitemid 126449555)
36. Rozendaal L, Pals ST, Melief CJ, Gleichmann E. Protection from lethal graft-vs-host disease by donor stem cell repopula-tion. Eur J Immunol 1992; 22: 575-579.
37. Ball LM, Lankester AC, Bredius RG, Fibbe WE, van Tol MJ, Egeler RM. Graft dysfunction and delayed immune recon-stitution following haploidentical peripheral blood hemato-poietic stem cell transplantation. Bone Marrow Transplant 2005; 35(Suppl 1): S35-S38. (Pubitemid 40613920)